{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:53:07Z","timestamp":1783601587258,"version":"3.55.0"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T00:00:00Z","timestamp":1553558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer with a distinctive regional and racial prevalence. It is associated with Epstein-Barr virus infection and has a high propensity for regional and distant metastases, while it is very sensitive to radiation and chemotherapy. A common feature of Epstein-Barr virus-positive NPC is the dense infiltration of lymphocytes in the tumor stroma and positive programmed death-ligand 1 expression in tumor cells, making it an attractive target for immunotherapy, especially immune checkpoint inhibitors. As new immunotherapeutic agents are being rapidly adopted in many cancers, including head and neck cancer, the National Cancer Institute sponsored a clinical trial planning meeting to identify opportunities for developing phase II and III trials testing immunotherapy in different stages of NPC. The meeting started with the summary of the biology of the disease, current standards of care, and evidence of immunotherapy in this cancer. Three subcommittees were tasked to develop clinical trials: loco regionally advanced, nonmetastatic NPC; widely metastatic NPC; and either local recurrence after initial treatment or presenting with oligometastatic disease. This article summarizes the proceedings of this clinical trial planning meeting and provides a road map for future trials incorporating immune checkpoint inhibitors for therapeutic management of NPC. This road map, though specific for NPC, may also be applicable to other virally driven cancers that have similar ability to evade the host\u2019s immune system.<\/jats:p>","DOI":"10.1093\/jnci\/djz044","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T20:20:31Z","timestamp":1553545231000},"page":"655-663","source":"Crossref","is-referenced-by-count":69,"title":["Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy"],"prefix":"10.1093","volume":"111","author":[{"given":"Quynh Thu","family":"Le","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Dimitrios","family":"Colevas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"O\u2019Sullivan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne W M","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigette","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, The Chinese University of Hong Kong, State Key Laboratory of Translational Oncology, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian L","family":"Siu","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Department of Medicine, Cancer Clinical Research Unit, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Waldron","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chwee-Ming","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem","family":"Riaz","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Lynn","sequence":"additional","affiliation":[{"name":"Clinical Investigative Branch, Cancer Therapy Evaluation Program, National Institute of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakun","family":"Malik","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Therapeutics"},{"name":"Clinical Investigative Branch, Cancer Therapy Evaluation Program, National Institute of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,26]]},"reference":[{"key":"2021031605310646800_djz044-B1","doi-asserted-by":"crossref","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2021031605310646800_djz044-B2","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.ijrobp.2017.03.018","article-title":"Clinical utility of Epstein-Barr virus DNA testing in the treatment of nasopharyngeal carcinoma patients","volume":"98","author":"Kim","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2021031605310646800_djz044-B3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1701717","article-title":"Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer","volume":"377","author":"Chan","year":"2017","journal-title":"N Engl J Med"},{"key":"2021031605310646800_djz044-B4","year":"2018"},{"issue":"14","key":"2021031605310646800_djz044-B5","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742)","volume":"36","author":"Ma","year":"2018","journal-title":"J Clin Oncol"},{"issue":"36","key":"2021031605310646800_djz044-B6","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","article-title":"Safety and antitumor activity of pembrolizumab in patients with programmed Death-Ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study","volume":"35","author":"Hsu","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"2021031605310646800_djz044-B7","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"},{"issue":"21","key":"2021031605310646800_djz044-B8","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1002\/cncr.30850","article-title":"A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity","volume":"123","author":"Lee","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"2021031605310646800_djz044-B9","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ijrobp.2018.04.069","article-title":"Concurrent-adjuvant chemoradiation therapy for Stage III-IVB nasopharyngeal carcinoma-exploration for achieving optimal 10-year therapeutic ratio","volume":"101","author":"Ng","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021031605310646800_djz044-B10","doi-asserted-by":"crossref","article-title":"Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial","author":"Chan","DOI":"10.1200\/JCO.2018.77.7847"},{"issue":"21","key":"2021031605310646800_djz044-B11","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/jnci\/94.21.1614","article-title":"Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma","volume":"94","author":"Chan","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"2021031605310646800_djz044-B12","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.1158\/1078-0432.CCR-05-0648","article-title":"A comparison study of different PCR assays in measuring circulating plasma Epstein-Barr virus DNA levels in patients with nasopharyngeal carcinoma","volume":"11","author":"Le","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2021031605310646800_djz044-B13","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma","volume":"350","author":"Lin","year":"2004","journal-title":"N Engl J Med"},{"issue":"27","key":"2021031605310646800_djz044-B14","doi-asserted-by":"crossref","first-page":"42608","DOI":"10.18632\/oncotarget.9323","article-title":"Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"2021031605310646800_djz044-B15","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx007","article-title":"Current state of PCR-based Epstein-Barr virus DNA testing for nasopharyngeal cancer","volume":"109","author":"Kim","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2021031605310646800_djz044-B16","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1158\/1078-0432.CCR-12-3702","article-title":"An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma","volume":"19","author":"Le","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2021031605310646800_djz044-B17","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"2021031605310646800_djz044-B18","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/cncr.29208","article-title":"Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma","volume":"121","author":"Lee","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"2021031605310646800_djz044-B19","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S1470-2045(11)70303-5","article-title":"Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol"},{"issue":"6","key":"2021031605310646800_djz044-B20","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00432-013-1419-z","article-title":"Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for loco regionally advanced nasopharyngeal carcinoma","volume":"139","author":"Niu","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"2021031605310646800_djz044-B21","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2217\/fon.13.151","article-title":"Cetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: preliminary results","volume":"9","author":"He","year":"2013","journal-title":"Future Oncol"},{"key":"2021031605310646800_djz044-B22","doi-asserted-by":"crossref","first-page":"14121","DOI":"10.1038\/ncomms14121","article-title":"Exome and genome sequencing of nasopharynx cancer identifies NF-kappaB pathway activating mutations","volume":"8","author":"Li","year":"2017","journal-title":"Nat Commun"},{"issue":"29","key":"2021031605310646800_djz044-B23","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1200\/JCO.2015.60.7846","article-title":"Nasopharyngeal cancer: molecular landscape","volume":"33","author":"Bruce","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"2021031605310646800_djz044-B24","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/CJI.0b013e3181f3cbf4","article-title":"Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma","volume":"33","author":"Louis","year":"2010","journal-title":"J Immunother"},{"issue":"2","key":"2021031605310646800_djz044-B25","doi-asserted-by":"crossref","first-page":"e976507.","DOI":"10.4161\/23723556.2014.976507","article-title":"Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma","volume":"4","author":"Li","year":"2015","journal-title":"Oncoimmunology"},{"issue":"2","key":"2021031605310646800_djz044-B26","doi-asserted-by":"crossref","first-page":"e1273311","DOI":"10.1080\/2162402X.2016.1273311","article-title":"Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: phenotype and effector function of T cells impact on clinical response","volume":"6","author":"Smith","year":"2017","journal-title":"Oncoimmunology"},{"issue":"5","key":"2021031605310646800_djz044-B27","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1182\/blood-2004-07-2975","article-title":"Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"issue":"21","key":"2021031605310646800_djz044-B28","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1002\/cncr.30198","article-title":"Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC\/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy","volume":"122","author":"Pan","year":"2016","journal-title":"Cancer"},{"issue":"10054","key":"2021031605310646800_djz044-B29","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial","volume":"388","author":"Zhang","year":"2016","journal-title":"Lancet"},{"issue":"22","key":"2021031605310646800_djz044-B30","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"2021031605310646800_djz044-B31","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1200\/JCO.2016.66.9861","article-title":"Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Rizvi","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"2021031605310646800_djz044-B32","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"2021031605310646800_djz044-B33","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/cncr.20358","article-title":"Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group","volume":"101","author":"Hui","year":"2004","journal-title":"Cancer"},{"issue":"2","key":"2021031605310646800_djz044-B34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3892\/etm.2012.584","article-title":"Challenges in the modification of the M1 stage of the TNM staging system for nasopharyngeal carcinoma: a study of 1027 cases and review of the literature","volume":"4","author":"Pan","year":"2012","journal-title":"Exp Ther Med"},{"issue":"7","key":"2021031605310646800_djz044-B35","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/cncr.30449","article-title":"Immunotherapy of head and neck cancer: emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting","volume":"123","author":"Bauman","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"2021031605310646800_djz044-B36","doi-asserted-by":"crossref","first-page":"e0126108.","DOI":"10.1371\/journal.pone.0126108","article-title":"Clinical outcome among nasopharyngeal cancer patients in a multi-ethnic society in Singapore","volume":"10","author":"Mak","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"2021031605310646800_djz044-B37","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/hed.21558","article-title":"Surgical salvage of persistent or recurrent nasopharyngeal carcinoma with maxillary swing approach\u2014critical appraisal after 2 decades","volume":"33","author":"Wei","year":"2011","journal-title":"Head Neck"},{"key":"2021031605310646800_djz044-B38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.oraloncology.2018.04.017","article-title":"Establishment of prognostic factors in recurrent nasopharyngeal carcinoma patients who received salvage intensity-modulated radiotherapy: a meta-analysis","volume":"81","author":"Yue","year":"2018","journal-title":"Oral Oncol"},{"issue":"9","key":"2021031605310646800_djz044-B39","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hed.24451","article-title":"Relapse status as a prognostic factor in patients receiving salvage surgery for recurrent or residual nasopharyngeal cancer after definitive treatment","volume":"38","author":"Chee","year":"2016","journal-title":"Head Neck"},{"issue":"1","key":"2021031605310646800_djz044-B40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0360-3016(03)00074-9","article-title":"Linear accelerator-based stereotactic radiosurgery for limited, locally persistent, and recurrent nasopharyngeal carcinoma: efficacy and complications","volume":"56","author":"Chua","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"18","key":"2021031605310646800_djz044-B41","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1016\/j.ejca.2012.06.016","article-title":"Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy","volume":"48","author":"Hua","year":"2012","journal-title":"Eur J Cancer"},{"issue":"3","key":"2021031605310646800_djz044-B42","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hed.24993","article-title":"Long-term outcomes after reirradiation in nasopharyngeal carcinoma with intensity-modulated radiotherapy: a meta-analysis","volume":"40","author":"Leong","year":"2018","journal-title":"Head Neck"},{"issue":"S1","key":"2021031605310646800_djz044-B43","doi-asserted-by":"crossref","first-page":"E594","DOI":"10.1002\/hed.24046","article-title":"Impact of resection margin status on outcome after salvage nasopharyngectomy for recurrent nasopharyngeal carcinoma","volume":"38","author":"Chan","year":"2016","journal-title":"Head Neck"},{"issue":"5","key":"2021031605310646800_djz044-B44","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(17)30179-1","article-title":"Proton therapy for head and neck cancer: expanding the therapeutic window","volume":"18","author":"Leeman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"2021031605310646800_djz044-B45","doi-asserted-by":"crossref","first-page":"25.","DOI":"10.21037\/cco.2016.03.05","article-title":"Proton therapy for nasopharyngeal carcinoma","volume":"5","author":"Holliday","year":"2016","journal-title":"Chin Clin Oncol"},{"issue":"2","key":"2021031605310646800_djz044-B46","doi-asserted-by":"crossref","first-page":"26.","DOI":"10.21037\/cco.2016.03.19","article-title":"Reirradiation of locally recurrent nasopharyngeal cancer: history, advances, and promises for the future","volume":"5","author":"Kong","year":"2016","journal-title":"Chin Clin Oncol"},{"issue":"1","key":"2021031605310646800_djz044-B47","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ijrobp.2016.02.036","article-title":"Proton beam reirradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes","volume":"95","author":"Romesser","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2021031605310646800_djz044-B48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijrobp.2016.03.053","article-title":"Reirradiation of head and neck cancers with proton therapy: outcomes and analyses","volume":"96","author":"Phan","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"2021031605310646800_djz044-B49","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/cncr.31318","article-title":"Salvage treatment using carbon ion radiation in patients with locoregionally recurrent nasopharyngeal carcinoma: initial results","volume":"124","author":"Hu","year":"2018","journal-title":"Cancer"},{"issue":"19","key":"2021031605310646800_djz044-B50","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"2021031605310646800_djz044-B51","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(17)30421-7","article-title":"Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial","volume":"18","author":"Harrington","year":"2017","journal-title":"Lancet Oncol"},{"issue":"20","key":"2021031605310646800_djz044-B52","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"2021031605310646800_djz044-B53","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/hed.24345","article-title":"Oligometastases in AJCC stage IVc nasopharyngeal carcinoma: a subset with better overall survival","volume":"38","author":"Tian","year":"2016","journal-title":"Head Neck"},{"issue":"2","key":"2021031605310646800_djz044-B54","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1002\/hed.24099","article-title":"Metastasectomy for metachronous pulmonary and hepatic metastases from nasopharyngeal carcinoma: report of 6 cases and review of the literature","volume":"38","author":"Lim","year":"2016","journal-title":"Head Neck"},{"issue":"3","key":"2021031605310646800_djz044-B55","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/jjco\/hyi245","article-title":"Treatment outcomes of patients with AJCC stage IVC nasopharyngeal carcinoma: benefits of primary radiotherapy","volume":"36","author":"Yeh","year":"2006","journal-title":"Jpn J Clin Oncol"},{"issue":"11","key":"2021031605310646800_djz044-B56","doi-asserted-by":"crossref","first-page":"201","DOI":"10.21037\/atm.2018.05.14","article-title":"The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis","volume":"6","author":"Ma","year":"2018","journal-title":"Ann Transl Med"},{"issue":"5","key":"2021031605310646800_djz044-B57","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"2021031605310646800_djz044-B58","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.18632\/oncotarget.2608","article-title":"EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy","volume":"5","author":"Fang","year":"2014","journal-title":"Oncotarget"},{"key":"2021031605310646800_djz044-B59","doi-asserted-by":"crossref","first-page":"43627","DOI":"10.1038\/srep43627","article-title":"PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"key":"2021031605310646800_djz044-B60","doi-asserted-by":"crossref","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"2021031605310646800_djz044-B61","first-page":"362","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","author":"Cristescu","year":"2018","journal-title":"Science"},{"issue":"9","key":"2021031605310646800_djz044-B62","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41588-018-0200-2","article-title":"Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors","volume":"50","author":"Miao","year":"2018","journal-title":"Nat Genet"},{"issue":"6334","key":"2021031605310646800_djz044-B63","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1126\/science.aak9510","article-title":"Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer","volume":"356","author":"Stevanovic","year":"2017","journal-title":"Science"},{"key":"2021031605310646800_djz044-B64","volume-title":"A Phase 2 Randomized Trial of Nivolumab with Stereotactic Body Radiotherapy (SBRT) vs Nivolumab Alone in Metastatic (M1) Head and Neck Squamous Cell Carcinoma","author":"McBride","year":"2018"},{"issue":"8","key":"2021031605310646800_djz044-B65","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","article-title":"Early assessment of lung cancer immunotherapy response via circulating tumor DNA","volume":"24","author":"Goldberg","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2021031605310646800_djz044-B66","article-title":"Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer","author":"Anagnostou","journal-title":"Cancer Res"},{"key":"2021031605310646800_djz044-B67","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","author":"McGranahan","journal-title":"Science"},{"issue":"6375","key":"2021031605310646800_djz044-B68","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"key":"2021031605310646800_djz044-B69","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2021031605310646800_djz044-B70","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/ng.601","article-title":"A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci","volume":"42","author":"Bei","year":"2010","journal-title":"Nat Genet"},{"issue":"6","key":"2021031605310646800_djz044-B71","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"issue":"7652","key":"2021031605310646800_djz044-B72","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"issue":"9","key":"2021031605310646800_djz044-B73","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S1470-2045(18)30413-3","article-title":"A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study","volume":"19","author":"Sun","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"2021031605310646800_djz044-B74","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"2021031605310646800_djz044-B75","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.oraloncology.2017.05.022","article-title":"Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG","volume":"71","author":"Le","year":"2017","journal-title":"Oral Oncol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djz044\/28697084\/djz044.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/111\/7\/655\/36609219\/djz044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/111\/7\/655\/36609219\/djz044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T05:40:58Z","timestamp":1615873258000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/111\/7\/655\/5420162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,26]]},"references-count":75,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,3,26]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djz044","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,3,26]]}}}